https://www.selleckchem.com/pr....oducts/tunicamycin.h
on of the NSE network. ICIs have strongly improved the outcome of NSCLC patients. However, primary and secondary resistance occur during treatment in most of the patients, with several of them developing fast progressions. Autoantibodies can be related with a dysfunctional immune system, although their association with immune-based anti-cancer therapies has never been investigated. Moreover, so far no reliable predictive factor is currently available to aid in treatment selection. CD137 T-cells are largely known to be the anti-tumor
Curtir
Comentario
Compartilhar
